Condensed Consolidated Statements of Stockholders' Deficit - USD ($) shares in Thousands, $ in Thousands		Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss (2)		Retained Earnings	Treasury Stock (3)		Noncontrolling Interests in Subsidiaries
Beginning balance (in shares) at Dec. 26, 2021			35,797
Beginning balance at Dec. 26, 2021		$ (172,458)	$ 490	$ 445,126	$ (9,971)	[1]	$ 183,157	$ (806,472)		$ 15,212
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[2]	10,917					10,494			423
Other comprehensive income (loss), net of tax		655			655	[1]
Dividends on common stock		(12,480)		47			(12,527)
Exercise of stock options (in shares)			17
Exercise of stock options		$ 741		741
Acquisition of Company common stock (in shares)		(301)	(301)
Acquisition of Company common stock		$ (32,709)						(32,709)
Stock-based compensation expense		4,176	$ 1	4,175
Issuance of restricted stock (in shares)			228
Issuance of restricted stock		0		(6,369)				6,369
Tax effect of restricted stock awards (in shares)			(69)
Tax effect of restricted stock awards		(7,461)		(7,461)
Other (in shares)			3
Other		175		(34)			0	209
Ending balance (in shares) at Mar. 27, 2022			35,675
Ending balance at Mar. 27, 2022		$ (208,444)	$ 491	436,225	(9,316)	[1]	181,124	(832,603)		15,635
Beginning balance (in shares) at Dec. 25, 2022		34,700	34,736
Beginning balance at Dec. 25, 2022		$ (270,664)	$ 491	449,829	(10,135)	[3]	195,856	(922,434)	[4]	15,729
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	[5]	22,500					22,376			124
Other comprehensive income (loss), net of tax		1,369			1,369	[3]
Dividends on common stock		(14,663)					(14,663)
Exercise of stock options (in shares)			15
Exercise of stock options		$ 614		614
Acquisition of Company common stock (in shares)		(2,523)	(2,523)
Acquisition of Company common stock		$ (212,444)						(212,444)	[4]
Stock-based compensation expense		3,898	$ 1	3,897
Issuance of restricted stock (in shares)			197
Issuance of restricted stock		0		(4,609)				4,609	[4]
Tax effect of restricted stock awards (in shares)			(72)
Tax effect of restricted stock awards		(5,999)		(5,999)
Distributions to noncontrolling interests		(23)								(23)
Other (in shares)			3
Other		$ 87		(46)				133	[4]
Ending balance (in shares) at Mar. 26, 2023		32,400	32,356
Ending balance at Mar. 26, 2023		$ (475,325)	$ 492	$ 443,686	$ (8,766)	[3]	$ 203,569	$ (1,130,136)	[4]	$ 15,830

[1] At March 27, 2022, the accumulated other comprehensive loss of $9,316 was comprised of net unrealized foreign currency translation loss of $5,533 and net unrealized loss on the interest rate swap agreements of $3,783.

[2] Net income to the Company for the three months ended March 27, 2022 excludes $510 allocable to the redeemable noncontrolling interests for our joint venture arrangements.

[3] At March 26, 2023, the accumulated other comprehensive loss of $8,766 was comprised of net unrealized foreign currency translation loss of $7,586 and net unrealized loss on the interest rate swap agreements of $1,180.

[4] Acquisition of Company common stock for the three months ended March 26, 2023 includes $2,804 of transaction costs directly attributable to share repurchases, including a 1% excise tax incurred under the Inflation Reduction Act of 2022.

[5] Net income to the Company for the three months ended March 26, 2023 excludes $46 allocable to the redeemable noncontrolling interests for our joint venture arrangements.